Get the Stockscreener App
13.35
3.96%
-0.55
After Hours:
13.63
0.28
+2.10%
Avalo Therapeutics Inc stock is traded at $13.35, with a volume of 497.88K.
It is down -3.96% in the last 24 hours and down -15.51% over the past month.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
See More
Previous Close:
$13.90
Open:
$14
24h Volume:
497.88K
Relative Volume:
0.82
Market Cap:
$304.23M
Revenue:
$59,000
Net Income/Loss:
$-78.26M
P/E Ratio:
-2.1898
EPS:
-6.0964
Net Cash Flow:
$-51.46M
1W Performance:
-7.36%
1M Performance:
-15.51%
6M Performance:
-3.96%
1Y Performance:
+172.45%
1-Day Range:
$13.34
$14.14
1-Week Range:
$13.15
$14.80
52-Week Range:
$3.39
$20.72
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Name
Avalo Therapeutics Inc
Sector
Industry
Phone
410-522-8707
Address
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
13.35 | 316.76M | 59,000 | -78.26M | -51.46M | -6.0964 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Wolfe Research | Outperform |
| Apr-06-26 | Initiated | Citizens | Mkt Outperform |
| Feb-02-26 | Initiated | Guggenheim | Buy |
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Sep-17-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-25 | Initiated | TD Cowen | Buy |
| Aug-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Mar-25-25 | Initiated | Jefferies | Buy |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-28-25 | Initiated | Piper Sandler | Overweight |
| Feb-21-25 | Initiated | Wedbush | Outperform |
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Oct-24-24 | Initiated | H.C. Wainwright | Neutral |
| Apr-16-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-24-21 | Initiated | RBC Capital Mkts | Outperform |
View All
Avalo Therapeutics Inc Stock (AVTX) Latest News
AVTX Reiterated by BTIG -- Price Target Maintained at $40 - GuruFocus
Short Squeeze: Can Avalo Therapeutics Inc grow without external funding2026 Setups & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Wall Street analysts predict an 113.34% upside in Avalo Therapeutics (AVTX): Here's what you should know - MSN
Breakout Move: Is Avalo Therapeutics Inc a potential multi baggerWeekly Profit Analysis & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Avalo Therapeutics (NASDAQ: AVTX) sets 2026 virtual meeting and ESPP changes - Stock Titan
Death Cross: Will Avalo Therapeutics Inc be affected by tariffsWeekly Loss Report & Daily Profit Focused Screening - baoquankhu1.vn
Wolfe Research initiates coverage of Avalo Therapeutics (AVTX) with outperform recommendation - MSN
AVTX: Wolfe Research Initiates Coverage with 'Outperform' Rating - GuruFocus
Wolfe Research Initiates Avalo Therapeutics(AVTX.US) With Buy Rating, Announces Target Price $48 - Moomoo
Aug Closing: Is Avalo Therapeutics Inc undervalued by DCF analysis2026 Weekly Recap & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Avalo Therapeutics: chief medical officer Doyle Mittie sells $71k in AVTX - Investing.com Canada
Avalo Therapeutics (AVTX) CMO exercises options, sells 3,970 shares in 10b5-1 trades - Stock Titan
Avalo Therapeutics, Inc. (AVTX) stock price, news, quote and history - Yahoo Finance UK
Citizens Initiates Coverage of Avalo Therapeutics (AVTX) with Market Outperform Recommendation - MSN
65,800-share Form 144 filed by AVTX (NASDAQ: AVTX) - Stock Titan
Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - Zacks Investment Research
This Avalo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Avalo Therapeutics (NASDAQ:AVTX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Avalo Therapeutics (NASDAQ:AVTX) Earns Market Outperform Rating from Analysts at Citizens Jmp - MarketBeat
Avalo Therapeutics Inc (AVTX) Stock News & Articles - 24/7 Wall St.
Citizens Initiates Coverage on Avalo Therapeutics (AVTX) with Ma - GuruFocus
Citizens JMP Initiates Avalo Therapeutics(AVTX.US) With Buy Rating, Announces Target Price $52 - Moomoo
Citizens initiates Avalo Therapeutics stock with outperform rating By Investing.com - Investing.com India
Citizens initiates Avalo Therapeutics stock with outperform rating - Investing.com
Avalo Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
AVTX Technical Analysis & Stock Price Forecast - Intellectia AI
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Average Rating of "Moderate Buy" by Analysts - marketbeat.com
Avalo Therapeutics (AVTX) CMO Doyle Mittie sells $10,864 in stock By Investing.com - Investing.com India
Insider Sell Alert: Christopher Sullivan Sells Shares of Avalo T - GuruFocus
Avalo Therapeutics (NASDAQ:AVTX) CFO Sells $133,807.83 in Stock - MarketBeat
Avalo Therapeutics (NASDAQ:AVTX) Insider Mittie Doyle Sells 679 Shares - MarketBeat
Avalo Therapeutics (NASDAQ:AVTX) CFO Christopher Ryan Sullivan Sells 7,980 Shares - MarketBeat
Avalo Therapeutics CFO Sullivan sells $270k in stock By Investing.com - Investing.com India
Avalo Therapeutics CFO Sullivan sells $270k in stock - Investing.com
Avalo Therapeutics (AVTX) CMO Doyle Mittie sells $10,864 in stock - Investing.com
Avalo Therapeutics (AVTX) CFO executes Rule 10b5-1 stock sale plan - Stock Titan
Avalo Therapeutics (AVTX) CMO exercises options, sells 679 pre-planned shares - Stock Titan
Wall Street experts anticipate Avalo Therapeutics (AVTX) could surge by 113.34%: Key Insights You Need to Know - Bitget
Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should Know - Yahoo Finance
[144] Avalo Therapeutics, Inc. SEC Filing - Stock Titan
Director at Avalo Therapeutics (NASDAQ: AVTX) receives 1,339 options - Stock Titan
Director at Avalo Therapeutics (NASDAQ: AVTX) receives 1,370 vested options - Stock Titan
Logos Global (AVTX) discloses 1,285,000-share position, including options - Stock Titan
Avalo Therapeutics Inc Stock (AVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):